Comparative Pharmacology
Head-to-head clinical analysis: PANMYCIN versus TERRAMYCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANMYCIN versus TERRAMYCIN.
PANMYCIN vs TERRAMYCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
Inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
250-500 mg orally every 6 hours or 1-2 g intravenously every 12 hours. Maximum oral dose: 2 g/day.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Terminal elimination half-life: 8-10 hours in normal renal function; prolonged to 20-40 hours in severe renal impairment (creatinine clearance <10 mL/min).
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Renal (primarily glomerular filtration, 20-60% unchanged in urine), biliary/fecal (10-30% via bile into feces).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic